KR20100126390A - 톨-유사 수용체 3의 선택적인 작용제 - Google Patents
톨-유사 수용체 3의 선택적인 작용제 Download PDFInfo
- Publication number
- KR20100126390A KR20100126390A KR1020107020663A KR20107020663A KR20100126390A KR 20100126390 A KR20100126390 A KR 20100126390A KR 1020107020663 A KR1020107020663 A KR 1020107020663A KR 20107020663 A KR20107020663 A KR 20107020663A KR 20100126390 A KR20100126390 A KR 20100126390A
- Authority
- KR
- South Korea
- Prior art keywords
- poly
- cells
- tlr3
- microorganism
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000008230 Toll-like receptor 3 Human genes 0.000 title claims abstract description 60
- 108010060885 Toll-like receptor 3 Proteins 0.000 title claims abstract description 60
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 239000000556 agonist Substances 0.000 claims abstract description 9
- 229920002477 rna polymer Polymers 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 210000004443 dendritic cell Anatomy 0.000 claims description 33
- 102000004127 Cytokines Human genes 0.000 claims description 31
- 108090000695 Cytokines Proteins 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- 244000005700 microbiome Species 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 102000002689 Toll-like receptor Human genes 0.000 claims description 10
- 108020000411 Toll-like receptor Proteins 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 230000016396 cytokine production Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 108090000944 RNA Helicases Proteins 0.000 claims description 3
- 102000004409 RNA Helicases Human genes 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 3
- 230000004041 dendritic cell maturation Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 230000000770 proinflammatory effect Effects 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 8
- 230000003308 immunostimulating effect Effects 0.000 abstract description 5
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 4
- 230000000845 anti-microbial effect Effects 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 description 63
- 238000002347 injection Methods 0.000 description 63
- 210000001744 T-lymphocyte Anatomy 0.000 description 47
- 238000001802 infusion Methods 0.000 description 40
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 38
- 108010074328 Interferon-gamma Proteins 0.000 description 26
- 239000002671 adjuvant Substances 0.000 description 26
- 102100037850 Interferon gamma Human genes 0.000 description 25
- 102100040247 Tumor necrosis factor Human genes 0.000 description 20
- 230000036039 immunity Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 19
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- 210000001616 monocyte Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000001681 protective effect Effects 0.000 description 14
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 13
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 13
- 230000002062 proliferating effect Effects 0.000 description 13
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 12
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 12
- 102100035793 CD83 antigen Human genes 0.000 description 11
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 11
- 206010046865 Vaccinia virus infection Diseases 0.000 description 11
- 230000035800 maturation Effects 0.000 description 11
- 208000007089 vaccinia Diseases 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 8
- 102100026720 Interferon beta Human genes 0.000 description 7
- 108090000467 Interferon-beta Proteins 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- 102100022297 Integrin alpha-X Human genes 0.000 description 6
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000007123 defense Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 241001493065 dsRNA viruses Species 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 4
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000450599 DNA viruses Species 0.000 description 3
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 3
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 3
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940029030 dendritic cell vaccine Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 2
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 2
- 240000005528 Arctium lappa Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000224467 Giardia intestinalis Species 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000007112 pro inflammatory response Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 1
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241001115070 Bornavirus Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000191796 Calyptosphaeria tropica Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241001290832 Campylobacter hominis Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000158508 Corynebacterium amycolatum Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000059461 Escherichia coli O175 Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000207155 Heliobacterium Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222724 Leishmania amazonensis Species 0.000 description 1
- 241000222740 Leishmania braziliensis Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000157299 Mycobacterium branderi Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 244000020186 Nymphaea lutea Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102100037434 Probable ATP-dependent RNA helicase DDX5 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000606726 Rickettsia typhi Species 0.000 description 1
- 241001534527 Roniviridae Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 101150029539 Tlr3 gene Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 108091007231 endothelial receptors Proteins 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011355 in situ vaccination Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2930708P | 2008-02-15 | 2008-02-15 | |
| US61/029,307 | 2008-02-15 | ||
| US5160608P | 2008-05-08 | 2008-05-08 | |
| US61/051,606 | 2008-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100126390A true KR20100126390A (ko) | 2010-12-01 |
Family
ID=40957440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107020663A Withdrawn KR20100126390A (ko) | 2008-02-15 | 2009-02-17 | 톨-유사 수용체 3의 선택적인 작용제 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100310600A1 (enExample) |
| EP (1) | EP2249845A4 (enExample) |
| JP (1) | JP2011525169A (enExample) |
| KR (1) | KR20100126390A (enExample) |
| CN (1) | CN101990435A (enExample) |
| AU (1) | AU2009215128A1 (enExample) |
| BR (1) | BRPI0907515A2 (enExample) |
| CA (1) | CA2715293A1 (enExample) |
| NZ (1) | NZ587371A (enExample) |
| WO (1) | WO2009102496A2 (enExample) |
| ZA (1) | ZA201005826B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110196020A1 (en) * | 2008-10-10 | 2011-08-11 | Carter William A | Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3) |
| US20100160413A1 (en) * | 2008-10-23 | 2010-06-24 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| US8722874B2 (en) | 2008-10-23 | 2014-05-13 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| NZ599677A (en) * | 2009-12-18 | 2014-10-31 | Bavarian Nordic As | Production of ifn-lambda by conventional dendritic cells and uses thereof |
| CN108853144A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
| CN108498362A (zh) * | 2018-04-17 | 2018-09-07 | 睿欧生物科技（上海）有限公司 | 预防及治疗口腔溃疡的Toll样受体激动剂漱口水 |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| CN115487302A (zh) * | 2022-11-09 | 2022-12-20 | 吉林大学 | Toll样受体3在治疗华支睾吸虫性肝纤维化的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4024222A (en) * | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
| US6130206A (en) * | 1980-07-07 | 2000-10-10 | Hem Research, Inc. | Treating viral infections associated with chronic fatigue with dsRNA |
| US6080726A (en) * | 1985-08-12 | 2000-06-27 | University Of Maryland | Anti-viral and immuno stimulator polynucleotide duplex and use thereof |
| US4795744A (en) * | 1986-07-17 | 1989-01-03 | Hem Research, Inc. | Modulation of AIDS virus-related events by double-stranded RNAS |
| US5063209A (en) * | 1985-08-26 | 1991-11-05 | Hem Research, Inc. | Modulation of aids virus-related events by double-stranded RNAs |
| US4950652A (en) * | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
| ZA883887B (en) * | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| US5258369A (en) * | 1988-08-29 | 1993-11-02 | Hem Pharmaceuticals Corporation | Treatment of chronic cerebral dysfunction by dsRNA methodology |
| GB0119346D0 (en) * | 2001-08-08 | 2001-10-03 | Bioclones Proprietary Ltd | Process for the maturation of dendritic cells |
| WO2003037323A2 (en) * | 2001-10-26 | 2003-05-08 | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction |
| WO2006054129A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| US7834064B2 (en) * | 2005-01-03 | 2010-11-16 | Andres Mario Salazar | Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs |
| JP2009518410A (ja) * | 2005-12-07 | 2009-05-07 | へミスフェリックス・バイオファーマ | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| AU2007280690C1 (en) * | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
| AU2008223446B2 (en) * | 2007-03-05 | 2012-02-02 | Utah State University | Restrictive agonist of Toll-like receptor 3 (TLR3) |
| JP2011518116A (ja) * | 2008-02-21 | 2011-06-23 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | トール様受容体３拮抗薬としての超小型ｒｎａ |
| US20110196020A1 (en) * | 2008-10-10 | 2011-08-11 | Carter William A | Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3) |
| US8722874B2 (en) * | 2008-10-23 | 2014-05-13 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| US20100160413A1 (en) * | 2008-10-23 | 2010-06-24 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| EP2405919A4 (en) * | 2009-03-13 | 2013-01-02 | Hemispherx Biopharma Inc | TREATMENT OF CHRONIC EXHAUST SYNDROME AND EXTENDED QT INTERVAL |
-
2009
- 2009-02-17 CA CA2715293A patent/CA2715293A1/en not_active Abandoned
- 2009-02-17 BR BRPI0907515-1A patent/BRPI0907515A2/pt not_active IP Right Cessation
- 2009-02-17 NZ NZ587371A patent/NZ587371A/xx not_active IP Right Cessation
- 2009-02-17 EP EP09710652A patent/EP2249845A4/en not_active Withdrawn
- 2009-02-17 WO PCT/US2009/000959 patent/WO2009102496A2/en not_active Ceased
- 2009-02-17 AU AU2009215128A patent/AU2009215128A1/en not_active Abandoned
- 2009-02-17 CN CN2009801126292A patent/CN101990435A/zh active Pending
- 2009-02-17 KR KR1020107020663A patent/KR20100126390A/ko not_active Withdrawn
- 2009-02-17 JP JP2010546793A patent/JP2011525169A/ja not_active Withdrawn
- 2009-02-17 US US12/735,755 patent/US20100310600A1/en not_active Abandoned
-
2010
- 2010-08-16 ZA ZA2010/05826A patent/ZA201005826B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009215128A1 (en) | 2009-08-20 |
| WO2009102496A2 (en) | 2009-08-20 |
| JP2011525169A (ja) | 2011-09-15 |
| US20100310600A1 (en) | 2010-12-09 |
| WO2009102496A3 (en) | 2009-11-05 |
| CN101990435A (zh) | 2011-03-23 |
| ZA201005826B (en) | 2011-10-26 |
| NZ587371A (en) | 2012-12-21 |
| EP2249845A2 (en) | 2010-11-17 |
| EP2249845A4 (en) | 2012-02-29 |
| CA2715293A1 (en) | 2009-08-20 |
| BRPI0907515A2 (pt) | 2015-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tamayo et al. | Poly (anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation | |
| Wille-Reece et al. | Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses | |
| Martins et al. | Vaccine adjuvant uses of poly-IC and derivatives | |
| Krieg | Therapeutic potential of Toll-like receptor 9 activation | |
| Wang et al. | STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice | |
| JP6792294B2 (ja) | 肺のがんを処置するためのポリヌクレオチドのＴｏｌｌ様受容体９アゴニストの肺内投与 | |
| Jeon et al. | Toll-like receptor agonists as cancer vaccine adjuvants | |
| KR20100126390A (ko) | 톨-유사 수용체 3의 선택적인 작용제 | |
| AU2008223446B2 (en) | Restrictive agonist of Toll-like receptor 3 (TLR3) | |
| US20070298051A1 (en) | Adjuvants Of Immune Response | |
| JP2019511552A (ja) | Ｃｄ４７遮断療法におけるマクロファージの刺激 | |
| JP2002500159A (ja) | 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用 | |
| US20250171507A1 (en) | Cpg amphiphiles and uses thereof | |
| US20130302278A1 (en) | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens | |
| CN103189072B (zh) | 免疫刺激方法 | |
| JP2005237328A (ja) | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド | |
| KR20190034210A (ko) | 암 면역 아쥬반트 | |
| JP2020510052A (ja) | 免疫賦活薬、免疫療法用医薬組成物、ならびにその調製および使用 | |
| EP4304606A1 (en) | Polysaccharide adjuvants for virus vaccines | |
| WO2012040266A2 (en) | Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines | |
| US20250152644A1 (en) | Recombinant oncolytic virus and use thereof | |
| CN107149671B (zh) | 一种药物组合物及其应用 | |
| CA3262130A1 (en) | Recombinant oncolytic virus and use thereof | |
| JP2017200914A (ja) | ケモカインｃｘｃｌ１４を利用した自然免疫活性化アジュバント | |
| WO2023009171A2 (en) | Optimized multidimensional biological activity of poly-iclc with controlled component size and formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100915 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |